Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized trial of thalidomide plus TACE versus TACE alone in hepatocellular carcinoma
ChiCTR-TRC-08000081Phase 2Completed
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thalidomide in hepatocellular carcinoma (HCC) (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: overall survival and time to progression. Started Aug 2004; status: completed.
02
Drugs
thalidomide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-08000081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-08000081.